A Study of Myofunctional Therapy After Sleep Apnea Surgery
Key facts
- Who runs it
- Taipei Medical University Shuang Ho Hospital
- Where
- Taiwan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 51 people enrolled
- Started
- 1 Jan 2020
- Ended
- 1 Jan 2024
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- myofunctional therapy
- Record updated
- 17 November 2025
Who can take part
- Age
- 20 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age 20-65 years
- Moderate-to-severe Obstructive Sleep Apnea (AHI ≥ 15 events/hour) confirmed by PSG
- Friedman palate position grade I-II and tonsil size grade III-IV
- Patients who refuse or are unable to tolerate CPAP
Who cannot take part
- Severe cardiopulmonary disease or psychiatric illness
- Pregnancy or cancer
- - Central or mixed sleep apnea
- BMI > 27 kg/m²
- Significant weight gain during the follow-up period
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Obstructive sleep apnea (OSA) is a common disorder characterized by recurrent upper airway collapse. While surgery is a common treatment, its success rates are variable. Myofunctional therapy (MFT), a program of targeted oropharyngeal exercises, has emerged as a promising adjunctive treatment to improve surgical outcomes.
Read full original descriptionShow less
This study prospectively compared outcomes in adult patients with moderate-to-severe OSA who received postoperative MFT (OP+MFT) versus those who underwent surgery alone (OP). Following surgery, patients were allocated to either the OP+MFT group, which began a 12-week MFT program, or the OP-only group. Polysomnography (PSG) was performed at baseline and at 3 and 12 months post-surgery.
The study found that the OP+MFT group showed significantly greater improvements in key sleep parameters, including the Apnea-Hypopnea Index (AHI) and lowest oxygen saturation, compared to the OP group. These benefits were most pronounced at the 3-month follow-up, supporting the conclusion that postoperative MFT is a safe and effective adjunct to surgery for OSA.
The 2 groups in the trial
- OP+MFT GroupTreatment being tested
Participants in this group underwent surgery and began a structured 12-week postoperative myofunctional therapy (MFT) program starting at the third postoperative week.
Treatment: myofunctional therapy
- OP-only GroupNo study treatment, for comparison
Participants in this group underwent the same surgical procedure but received only routine postoperative follow-up without any additional MFT training.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Postoperative Myofunctional Therapy Enhances Surgical Outcomes in Patients With Obstructive Sleep Apnea: A Prospective Comparative Stud
- Record updated
- 17 November 2025